This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second View: Getting an endocrinologist's view on Rezvoglar and other available interchangeable biosimilar insulin products in managing diabetes
Ticker(s): LLY, SNY, VTRSVWho's the expert?
Institution: University of Texas
- Assistant Professor of Endocrinology at Univeristy of Texas.
- Treats 600 patients with Type-2 Diabetes.
- Clinical interests include adrenal pathology, calcium disorders, endocrine neoplasia and resistant hypertension.
Interview GoalThis conversation will focus on the biosimilar insulin market landscape with a focus on Rezvoglar, Semglee, and Lantus. The FDA approved for Rezvoglar (insulin glargine-aglr), a biosimilar for Lantus (insulin glargine) that was originally approved in December 2021, for an interchangeability designation, allowing the product to be exchanged for the reference product at the pharmacy level without requiring physician permission.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
